You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Related Medications Videos on Diabetes Health TV
Nuevas Pequeñas Molécula Drogas Para El Tipo 2 - Ensayos Humanos En Curso
New Small Molecule Drugs for Type 2 - Human Trials Underway
STAT™ Medical Devices
Popular GLP-1 Articles
Highly Recommended GLP-1 Articles
We’ve all heard a lot of discussion about low carbohydrate diets and whether they are effective for weight loss and blood sugar control.. What most of us do not understand, however, is how diabetes affects the way that we process carbs. Beta cells make more than insulin: they also make another satiety hormone: amylin. If we are beta-cell deficient, then we are amylin-deficient as well. When the amylin hormone is not available to tell our brain that we are full, we crave more food, especially carbohydrates. Carbohydrates act as a mood stabilizer, making us feel good when we’re stressed.
0 comments - Aug 31, 2012 -
Readers occasionally ask us for advice about drugs they are taking. When they do, we refer their questions to a medical professional. In the question below, a Florida reader expresses concerns about the interaction of her diabetes drug with the medicines she takes for asthma.
0 comments - Mar 29, 2012 -
After several years of delays and setbacks, Amylin Pharmaceuticals has received FDA approval to begin US marketing of BydureonTM. The first once-a-week type 2 therapy to be offered in the US market, Bydureon is expected to be available by February. Amylin says that its wholesale price will be about $4,200 a year.
0 comments - Feb 3, 2012 -
News from Danish pharmaceutical manufacturer Novo Nordisk reinforces the growing trend toward using a two-drug combination in the early treatment of type 2 diabetes. (See "A Conversation About Janumet and Earlier Combination Therapy Type 2 Diabetes" for more discussion about the phenomenon.)
0 comments - Dec 15, 2011 -
News from Danish pharmaceutical manufacturer Novo Nordisk reinforces the growing trend toward using a two-drug combination in the early treatment of type 2 diabetes. (See "A Conversation About Janumet and Earlier Combination Therapy for Type 2 Diabetes" for more discussion about this phenomenon.) In a study it released in Lisbon, Portugal, at the recent meeting of the European Association for the Study of Diabetes, Novo said that combining its recently released drug Victoza® (liraglutide) with another drug early in therapy helps recently diagnosed type 2s achieve greater blood glucose control than they can with a single drug.
0 comments - Oct 2, 2011 -
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.